{"analyses":[{"ciLowerLimit":"0.55","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.93","groupDescription":"Pain in Chest: Stratified analysis based on the strata of IC levels per IxRS, the number of prior chemotherapy regimens per IxRS, and histology per eCRF.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0111","paramType":"Hazard Ratio (HR)","paramValue":"0.72","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.84","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.33","groupDescription":"Cough: Unstratified Analysis","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.6305","paramType":"Hazard Ratio (HR)","paramValue":"1.06","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.81","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.16","groupDescription":"Dyspnea: Unstratified Analysis","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.7406","paramType":"Hazard Ratio (HR)","paramValue":"0.97","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.73","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.17","groupDescription":"Arm/Shoulder Pain","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.5221","paramType":"Hazard Ratio (HR)","paramValue":"0.92","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.6","upperLimit":"12.5","value":"8.3"},{"comment":"Data not reported because the upper limit of CI was not estimable due to higher number of censored participants.","groupId":"OG001","lowerLimit":"11.0","upperLimit":"NA","value":"18.0"}]}],"title":"Pain in Chest"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.0","upperLimit":"12.8","value":"5.6"},{"groupId":"OG001","lowerLimit":"4.2","upperLimit":"7.9","value":"5.5"}]}],"title":"Cough"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.6","upperLimit":"2.3","value":"2.1"},{"groupId":"OG001","lowerLimit":"1.5","upperLimit":"2.3","value":"1.8"}]}],"title":"Dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.9","upperLimit":"14.7","value":"6.2"},{"groupId":"OG001","lowerLimit":"5.8","upperLimit":"12.8","value":"8.3"}]}],"title":"Arm/Shoulder Pain"}],"denoms":[{"counts":[{"groupId":"OG000","value":"425"},{"groupId":"OG001","value":"425"}],"units":"Participants"}],"description":"TTD in patient-reported lung cancer symptoms (pain in chest or in arm/shoulder, dyspnea, or cough) was a composite endpoint defined as the time from randomization to the earliest time the participant's scale scores showed a 10 point or greater increase after baseline in any of the symptoms. A \\>/=10-point change in the score perceived by participants was considered as clinically significant. The QLQ-LC13 consisted of 1 multi-item scale and 9 single items that assessed the specific symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia), and pain medication use of lung cancer participants receiving chemotherapy. Scale score range: 0 to 100. Higher symptom score = greater degree of symptom severity.","dispersionType":"95% Confidence Interval","groups":[{"description":"Docetaxel 75 milligrams per square meter (mg/m\\^2) was administered intravenously (IV) on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.","id":"OG000","title":"Docetaxel"},{"description":"Atezolizumab 1200 mg was administered IV on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.","id":"OG001","title":"Atezolizumab"}],"paramType":"MEDIAN","populationDescription":"The PP-ITT analysis set.","reportingStatus":"POSTED","timeFrame":"Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years) (1 Cycle = 21 days)","title":"Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms, Using the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire (QLQ) Lung Cancer Supplemental Module 13 (LC13)","type":"SECONDARY","unitOfMeasure":"Months"}